PE70398A1 - Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa - Google Patents

Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa

Info

Publication number
PE70398A1
PE70398A1 PE1997000433A PE00043397A PE70398A1 PE 70398 A1 PE70398 A1 PE 70398A1 PE 1997000433 A PE1997000433 A PE 1997000433A PE 00043397 A PE00043397 A PE 00043397A PE 70398 A1 PE70398 A1 PE 70398A1
Authority
PE
Peru
Prior art keywords
formula
compounds
alkyl
substituted
salts
Prior art date
Application number
PE1997000433A
Other languages
English (en)
Inventor
Silvio Roggo
Kaspar Zimmermann
Claudia Betschart
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE70398A1 publication Critical patent/PE70398A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14—[b,f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: ALK DE PREFERENCIA ES ALQUILIDENO INFERIOR; R ES UN GRUPO AMINO INSUSTITUIDO O SUSTITUIDO, POR ALQUILO C1-C4, POR FENILALQUILO C1-C4 (EN DONDE LA PARTE ALQUILICA ESTA SUSTITUIDA POR CARBOXI EVENTUALMENTE ESTERIFICADO), POR FENILALQUILENO C1-C4 O POR FENILALQUILO C1-C4-ALQUILENO C1-C4, ENTRE OTROS; R1, R2, R3 Y R4 SON H, ALQUILO C1-C4, ALCOXI C1-C4, HALOGENO, CF3. TAMBIEN SE REFIEREN A LAS SALES DE ADICION DE LOS COMPUESTOS DE FORMULA (I) Y AL PROCEDIMIENTO DE PREPARACION DE DICHA SAL, QUE COMPRENDE HACER REACCIONAR EL COMPUESTO DE FORMULA (I) EN FORMA LIBRE CON UN ACIDO ORGANICO TAL COMO EL ACIDO OXALICO, FUMARICO, MALEICO, SUCCINICO, DIMALEICO O DIFUMARICO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) Y SUS SALES DE ADICION SON UTILES PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS ESPECIALMENTE AQUELLAS RELACIONADAS A LA MUERTE CELULAR APOPTOTICA, TAL COMO ISQUEMIA CEREBRAL, LAS ENFERMEDADES DE ALZHEIMER, HUNTINGTON Y PARKINSON, LA ESCLEROSIS MULTIPLE Y LAS DIVERSAS CLASES DE GLAUCOMA, ASI COMO TAMBIEN EN EL TRATAMIENTO DE NEUROPATIAS PERIFERICAS GENERALES O DIABETICAS
PE1997000433A 1996-05-30 1997-05-28 Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa PE70398A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH135296 1996-05-30

Publications (1)

Publication Number Publication Date
PE70398A1 true PE70398A1 (es) 1998-11-09

Family

ID=4208469

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1997000433A PE70398A1 (es) 1996-05-30 1997-05-28 Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa

Country Status (10)

Country Link
AR (1) AR008371A1 (es)
AU (1) AU3030397A (es)
CO (1) CO5080765A1 (es)
CZ (1) CZ296134B6 (es)
ID (1) ID18178A (es)
PE (1) PE70398A1 (es)
PL (1) PL191728B1 (es)
TR (1) TR199802482T2 (es)
WO (1) WO1997045422A1 (es)
ZA (1) ZA974802B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
WO2003057204A2 (en) * 2002-01-08 2003-07-17 Nordic Bioscience A/S Modulation of iamt (pimt or pcmt) in immune system
JP2006516580A (ja) * 2003-01-29 2006-07-06 ノバルティス アクチエンゲゼルシャフト 眼の変性疾患の処置のための１０−アミノアリファチル−ジベンズ［ｂ，ｆ］オキセピンの使用
PE20050487A1 (es) * 2003-11-06 2005-10-07 Novartis Ag Composiciones farmaceuticas estabilizadas
MX2007003032A (es) 2004-09-21 2007-05-21 Hypnion Inc Analogos de loxapina y metodos de uso de los mismos.
US7563785B2 (en) 2004-10-29 2009-07-21 Hypnion, Inc. Quetiapine analogs and methods of use thereof
EP1757284A1 (en) 2005-08-25 2007-02-28 Santhera Pharmaceuticals (Schweiz) AG Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy
EP1842539A1 (en) * 2006-04-05 2007-10-10 Santhera Pharmaceuticals (Schweiz) AG Use of N- (dibenz(b,f)oxepin-10-ylmethyl)N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of congenital muscular dystrophy or myopathy resulting from collagen VI deficiency
WO2014120885A1 (en) 2013-01-30 2014-08-07 The Johns Hopkins University Treatment of drug abuse by preventing gapdh nitrosylation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100207A (en) * 1959-07-08 1963-08-06 Smith Kline French Lab 10-aminoalkylbenzo[b,f]thiepin and -dibenz[b,f]oxepin derivatives
DE1493782B1 (de) * 1964-06-29 1969-12-11 Geigy Ag J R Basisch substituierte Dibenzo[b,f]-oxepine und deren nicht-toxische Salze
CH585747A5 (es) * 1973-06-08 1977-03-15 Hoffmann La Roche
ES2160790T3 (es) * 1995-02-08 2001-11-16 Novartis Ag 10-aminoalifatil-dibenzo(b,f)oxepinas de accion antineurodegenerativa.

Also Published As

Publication number Publication date
WO1997045422A1 (en) 1997-12-04
ZA974802B (en) 1998-11-30
AR008371A1 (es) 2000-01-19
CZ387898A3 (cs) 1999-02-17
ID18178A (id) 1998-03-12
PL191728B1 (pl) 2006-06-30
CZ296134B6 (cs) 2006-01-11
PL330238A1 (en) 1999-05-10
AU3030397A (en) 1998-01-05
CO5080765A1 (es) 2001-09-25
TR199802482T2 (xx) 1999-02-22

Similar Documents

Publication Publication Date Title
PE70398A1 (es) Sales de 10-aminoalifatil-dibenz [b,f] oxepina con actividad antineurodegenerativa
CR7496A (es) Piridinoilpiperidinas como agonistas de 5- ht1f
PT88307A (pt) Processo de preparacao de uma composicao para a imunizacao de plantas contra microrganismos fitopatogenicos contendo derivados de 1,2,3-benzotiadiazol
KR870001151A (ko) 지질분해 활성을 갖는 신규 페닐에탄올 아미노테트랄린의 제조방법
AR003472A1 (es) Un procedimiento para preparar un alcohol terciario, un compuesto derivado de alfa-halo-alquil pirimidina y un compuesto intermediario para preparar 6-(1-bromoetil)-4-cloro-5-fluoropirimidina
CO4920223A1 (es) Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona 8- sustituidos
AR241591A1 (es) Procedimiento pra la preparacion de nuevos derivados de piperazina con actividad antianafilactica y broncoespasmolitica.
PE20000055A1 (es) Compuestos de indol 2,3-sustituidos como agentes anti-inflamatorios y analgesicos
DK0599890T3 (da) Geneserinderivater som cholinesteraseinhibitorer
GT200000049A (es) Compuestos quimicos.
KR850008666A (ko) 치환된 비스-(4-아미노페닐)-설폰의 제조방법
PT96030A (pt) Processo para a preparacao de aminocarbonilcarbamatos relacionados com fisoestigmina e de composicoes farmaceuticas que os contem
KR900012890A (ko) 환-치환된 2-아미노-1,2,3,4-테트라하이드로 나프탈렌 및 3-아미노크로만
BR8601946A (pt) Composto regulador de crescimento de plantas,processo para sua preparacao,composicao reguladora de crescimento de plantas e processo para regular o crescimento de plantas
PT93535A (pt) Processo para preparacao de derivados da eserolina e de composicoes farmaceuticas que os contem
PE20030517A1 (es) Composicion fungicida a base de al menos un derivado de piridil-metil-benzamida y de al menos un derivado ditio-carbamato
ES2103113T3 (es) Acido (7s)-7-(2r)-2-(3-clorofenil)-2-hidroxietilamino-5,6,7,8-tetrahidronaftalen-2-iloxi acetico, sus sales farmaceuticamente aceptables, de accion agonista beta3 adrenergica, composiciones farmaceuticas y reactivos de laboratorio que lo contienen.
ATE22685T1 (de) Substituierte 1,3-diazolyl-2-propanole, verfahren zu ihrer herstellung und ihre verwendung als antimykotische mittel.
AR005226A1 (es) Herbicidas de 3-fenil-pirazol sustituidos
PE20241633A1 (es) Inhibidores de protoporfirinogeno oxidasa
CA2470066A1 (en) 3-phenyl-2-arylalkylthiopropionic acid derivatives as selective agonists of ppar-alpha
PT89064A (pt) Processo para a preparacao de compostos piperidinil-1,4-dissubstituidos com accao analgesica e miorrelaxante
EP1346988A4 (en) METHOD FOR PRODUCING OPTICALLY ACTIVE 2,4-DIHYDROBENZOFURANE COMPOUNDS
BRPI0512249A (pt) compostos, processos para a preparação dos mesmos, e para o combate de fungos nocivos fitopatogênicos, agente fungicida, e, semente
ES2056868T3 (es) Enoleteres de 6-cloro-4-hidroxi-2-metil-n-(2-piridil)-2h-tienol(3,3-e)-1,2-tiazin-3-carboxiamida-1,1-dioxido, un procedimiento para su obtencion asi como su empleo.

Legal Events

Date Code Title Description
FG Grant, registration
MK Expiration of term